Development and validation of a revised instrument to measure burden of long-term medicines use: the Living with Medicines Questionnaire version 3
Open Access
- 1 May 2018
- journal article
- research article
- Published by Taylor & Francis in Patient Related Outcome Measures
- Vol. ume 9, 155-168
Abstract
Objectives: To revise the Living with Medicines Questionnaire version 2 (LMQ-2), which measures the burden of using prescribed medicines, to include cost and expand side effects and social issues. Methods: New statements were developed and validated through cognitive interviews with medicine users, and these and a global visual analog scale (VAS) were added to the 42-item LMQ-2. Construct validity was assessed through exploratory and confirmatory factor analyses using an online public survey. Criterion-related validity was measured against the Treatment Satisfaction Questionnaire with Medication (TSQM-II) and the EuroQoL 5-level quality of life measure (EQ-5D-5L), in patients using community pharmacies, general practices, and outpatient clinics. Reliability was assessed by test–retest using online public distribution. Results: The 58-item interim instrument (n=729) was reduced to 41 items after factor analysis, which confirmed an eight-domain structure: relationships with health professionals, practicalities, interferences, effectiveness, side effects, concerns, cost, and autonomy, constructed as medicine burden. All subscales, except autonomy, were loaded onto this construct and showed acceptable internal consistency. LMQ-VAS correlated with total LMQ scores (r=0.571). Criterion validation (n=422) demonstrated total LMQ scores negatively correlated with TSQM scores for global satisfaction (r=– 0.616); domain scores showed similar correlations: effectiveness (r=–0.628), side effects (r=–0.597), and practicalities (r=–0.529). Total LMQ score was negatively correlated with EQ VAS (r=–0.383) and showed weak/moderate relationships with individual EQ-5D-5L dimensions. Test–retest (n=30) reliability showed intra-class correlation coefficients of 0.954 (total LMQ score), 0.733–0.929 (domain scores), and 0.789 (global item). Conclusion: The LMQ version 3 (LMQ-3) instrument has acceptable construct, criterion-related and known-groups validity, and is internally consistent as a measure of medicine burden, although reliability requires further confirmation. It could be used to measure the outcome of interventions designed to reduce the burden of polypharmacy.Keywords
This publication has 27 references indexed in Scilit:
- A systematic review of patient-reported measures of burden of treatment in three chronic diseasesPatient Related Outcome Measures, 2013
- Development and description of measurement properties of an instrument to assess treatment burden among patients with multiple chronic conditionsBMC Medicine, 2012
- Polypharmacy: When Is Enough, Enough?Geriatric Nursing, 2011
- Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L)Quality of Life Research, 2011
- The COSMIN checklist for assessing the methodological quality of studies on measurement properties of health status measurement instruments: an international Delphi studyQuality of Life Research, 2010
- Patients' views on the UK policy of prescription charges—Insights from qualitative interviewsResearch in Social and Administrative Pharmacy, 2008
- Quality criteria were proposed for measurement properties of health status questionnairesJournal of Clinical Epidemiology, 2007
- Hierarchical Construct Validity of the Treatment Satisfaction Questionnaire for Medication (TSQM Version II) among Outpatient Pharmacy ConsumersValue in Health, 2005
- Resisting medicines: a synthesis of qualitative studies of medicine takingSocial Science & Medicine, 2005
- Measuring treatment impact: a review of patient-reported outcomes and other efficacy endpoints in approved product labelsControlled Clinical Trials, 2004